Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report
Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | cat |
| Published: |
MDPI
2021
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10835/9523 |
| _version_ | 1789408399728836608 |
|---|---|
| author | Bustos, Antonio Selvi Sabater, Pablo Benlloch, María Drehmer, Eraci López-Rodríguez, María Mar Platero, Felix Platero, Jose Luis Escribá-Alepuz, Jesús Rubia Ortí, Jose Enrique de la |
| author_facet | Bustos, Antonio Selvi Sabater, Pablo Benlloch, María Drehmer, Eraci López-Rodríguez, María Mar Platero, Felix Platero, Jose Luis Escribá-Alepuz, Jesús Rubia Ortí, Jose Enrique de la |
| author_sort | Bustos, Antonio |
| collection | DSpace |
| description | Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease. |
| format | info:eu-repo/semantics/article |
| id | oai:repositorio.ual.es:10835-9523 |
| institution | Universidad de Cuenca |
| language | cat |
| publishDate | 2021 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oai:repositorio.ual.es:10835-95232023-04-12T19:17:57Z Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report Bustos, Antonio Selvi Sabater, Pablo Benlloch, María Drehmer, Eraci López-Rodríguez, María Mar Platero, Felix Platero, Jose Luis Escribá-Alepuz, Jesús Rubia Ortí, Jose Enrique de la Charcot-Marie-Tooth disease type 2 epigallocatechin gallate IL-6 motor activity paraoxonase 1 Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease. 2021-02-01T09:12:50Z 2021-02-01T09:12:50Z 2021-01-24 info:eu-repo/semantics/article 1010-660X, http://hdl.handle.net/10835/9523 cat https://www.mdpi.com/1010-660X/57/2/104 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess MDPI |
| spellingShingle | Charcot-Marie-Tooth disease type 2 epigallocatechin gallate IL-6 motor activity paraoxonase 1 Bustos, Antonio Selvi Sabater, Pablo Benlloch, María Drehmer, Eraci López-Rodríguez, María Mar Platero, Felix Platero, Jose Luis Escribá-Alepuz, Jesús Rubia Ortí, Jose Enrique de la Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report |
| title | Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report |
| title_full | Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report |
| title_fullStr | Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report |
| title_full_unstemmed | Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report |
| title_short | Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report |
| title_sort | metabolic and functional improvements in a patient with charcot-marie-tooth disease type 2 after egcg administration: a case report |
| topic | Charcot-Marie-Tooth disease type 2 epigallocatechin gallate IL-6 motor activity paraoxonase 1 |
| url | http://hdl.handle.net/10835/9523 |
| work_keys_str_mv | AT bustosantonio metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT selvisabaterpablo metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT benllochmaria metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT drehmereraci metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT lopezrodriguezmariamar metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT platerofelix metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT platerojoseluis metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT escribaalepuzjesus metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport AT rubiaortijoseenriquedela metabolicandfunctionalimprovementsinapatientwithcharcotmarietoothdiseasetype2afteregcgadministrationacasereport |